TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28438273

Group type: EXPERIMENTAL
Intervention: Antenatal yoga program (1‐h supervised yoga class, three times a week, starting at 26 weeks gestation)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Antenatal yoga program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 25542917

Group type: EXPERIMENTAL
Intervention: Nicotine lozenges
Number of subjects: 120

Group type: COMPARATOR
Intervention: Nicotine inhalers
Number of subjects: 120

Group type: COMPARATOR
Intervention: NRT strength of sensation scores
Number of subjects: 120

Group type: COMPARATOR
Intervention: Taste receptor genotype
Number of subjects: 120
Study: 23576518

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) group intervention, 8 weeks duration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study: 22436438

Group type: EXPERIMENTAL
Intervention: Beginning readers (six and eight years old) in the Identity condition
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Beginning readers (six and eight years old) in the Variation condition
Number of subjects: 3

Group type: COMPARATOR
Intervention: Preliterate children
Number of subjects: 3
Study: 19482902

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ultrasound Therapy (US)
Number of subjects: 70
Study: 16945487

Group type: EXPERIMENTAL
Intervention: brief coping skills intervention
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: brief motivational enhancement intervention
Number of subjects: 98

Group type: COMPARATOR
Intervention: waiting list condition
Number of subjects: 98
Study: 14709949

Group type: EXPERIMENTAL
Intervention: Haloperidol 15 mg/d
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Thioridazine 300 mg/d
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/d
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Quetiapine 750 mg/d
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Risperidone 6-8 mg/d increased to 16 mg/d
Number of subjects: 164

Group type: COMPARATOR
Intervention: Metabolic inhibition (concomitant administration of CYP450 inhibitors)
Number of subjects: 164
Study: 11333687

Group type: EXPERIMENTAL
Intervention: Intensive group asthma education program
Number of subjects: 73

Group type: COMPARATOR
Intervention: Individual and simplified education with a self‐management plan
Number of subjects: 73
Study: 9142503

Group type: EXPERIMENTAL
Intervention: Red spectral light
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Green spectral light
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Yellow spectral light
Number of subjects: 92

Group type: COMPARATOR
Intervention: Blue spectral light
Number of subjects: 92

Group type: COMPARATOR
Intervention: White light
Number of subjects: 92
Study: 7812225

Group type: EXPERIMENTAL
Intervention: Thermography measurements using Agema 870 thermovision unit
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thermography measurements for specific diagnoses (osteosarthrosis, internal derangement, normal)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Temperature measures from thermography
Number of subjects: 80
Study: 2961818

Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine (40-micrograms dose)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Recombinant-derived vaccine (40-micrograms and 20-micrograms doses)
Number of subjects: 61
Study: 30305151

Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Exercise (CAE)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise with Motor Complexity (AEMC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-exercising control (C)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CAE and AEMC
Number of subjects: 75
Study: 28058748

Group type: EXPERIMENTAL
Intervention: Acupressure (12 sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 100
Study: 26258145

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg (group C)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Ramosetron 0.3 mg (group A)
Number of subjects: 51
Study: 23107669

Group type: EXPERIMENTAL
Intervention: Fit-4-Fun Program (8-week intervention)
Number of subjects: 213
Study: 21415358

Group type: EXPERIMENTAL
Intervention: WHEL dietary intervention
Number of subjects: 447

Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Baseline bioavailable testosterone
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Higher baseline total testosterone
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Higher baseline bioavailable testosterone
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Lower baseline total testosterone
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Lower baseline bioavailable testosterone
Number of subjects: 447
Study: 17657228

Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin-enriched formula (EF)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 216
Study: 16792285

Group type: EXPERIMENTAL
Intervention: Neurorehabilitation targeted to dyscoordination, weakness, and dysfunctional task component execution
Number of subjects: 0
Study: 14528615

Group type: EXPERIMENTAL
Intervention: Education plus monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring-only
Number of subjects: 0
Study: 11033978

Group type: EXPERIMENTAL
Intervention: Successful weight maintenance over three years
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Successful weight loss and maintenance
Number of subjects: 854

Group type: EXPERIMENTAL
Intervention: Weight gain within the first twelve months
Number of subjects: 854
Study: 9387643

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide pulse therapy every 2 weeks (15 mg/kg per pulse)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulse therapy every 4 weeks (15 mg/kg per pulse)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 52
Study: 1575253

Group type: EXPERIMENTAL
Intervention: Experimental psychiatric consultation
Number of subjects: 741

Group type: COMPARATOR
Intervention: Baseline control
Number of subjects: 741

Group type: COMPARATOR
Intervention: Contemporaneous control
Number of subjects: 741
Study: 6374280

Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg oral dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg oral dose with standard breakfast
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31794575

Group type: EXPERIMENTAL
Intervention: Risk-glorifying commercial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral commercial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arousal condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-arousal condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accessibility to risk-positive cognitions
Number of subjects: 0
Study: 29452178

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 200
Study: 27379776

Group type: EXPERIMENTAL
Intervention: Laser 904 nm
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LED 945 nm
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 25390695

Group type: EXPERIMENTAL
Intervention: Levosimendan (25 hours infusion)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Levosimendan and Placebo (comparison)
Number of subjects: 61
Study: 23075178

Group type: EXPERIMENTAL
Intervention: Ustekinumab 1 mg/kg
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Ustekinumab 3 mg/kg
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/kg
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Ustekinumab (maintenance) 90 mg
Number of subjects: 526

Group type: COMPARATOR
Intervention: Placebo (maintenance)
Number of subjects: 526
Study: 20156909

Group type: EXPERIMENTAL
Intervention: Combination of medroxyprogesterone (500 mg/day) or megestrol acetate (320 mg/day), oral supplementation with eicosapentaenoic acid, L-carnitine (4 g/day), thalidomide (200 mg/day)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/day)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: L-carnitine (4 g/day)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Oral supplementation with eicosapentaenoic acid
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (500 mg/day) or Megestrol acetate (320 mg/day)
Number of subjects: 332
Study: 17360171

Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg QID + 200 microg beclomethasone dipropionate (BDP) BID
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Zileuton 400 mg QID + 200 microg beclomethasone dipropionate (BDP) BID
Number of subjects: 100

Group type: COMPARATOR
Intervention: Beclomethasone 400 microg BID
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 100
Study: 16352931

Group type: EXPERIMENTAL
Intervention: Goserelin (GOS) 3.6 mg/4 weeks for 2 years
Number of subjects: 207

Group type: COMPARATOR
Intervention: Goserelin (GOS)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day
Number of subjects: 207
Study: 12140499

Group type: EXPERIMENTAL
Intervention: Family presence during invasive procedures and resuscitations
Number of subjects: 20
Study: 9595984

Group type: EXPERIMENTAL
Intervention: EPDF
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: ARJP/EPDF
Number of subjects: 53
Study: 7666098

Group type: EXPERIMENTAL
Intervention: Standard CHOP (full doses every 3 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Weekly CHOP (one-third doses weekly)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Standard CHOP
Number of subjects: 38

Group type: COMPARATOR
Intervention: Weekly CHOP
Number of subjects: 38
Study: 2540245

Group type: EXPERIMENTAL
Intervention: S-ACV (daily suppressive oral acyclovir)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PLC/ACV (placebo and acyclovir for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (infrequently recurring genital HSV-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both S-ACV and PLC/ACV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subpopulation given a second year of S-ACV
Number of subjects: 0
Study: 31622044

Group type: EXPERIMENTAL
Intervention: Micronutrient powders (MNP) delivered by community volunteers alongside early childhood development interventions and seasonal malaria chemoprevention.
Number of subjects: 0
Study: 28364165

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.4% (n = 30)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal saline (n = 30)
Number of subjects: 54
Study: 26429115

Group type: EXPERIMENTAL
Intervention: Stage-matched multiple-behavior intervention (n=332)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Active control condition (n=52)
Number of subjects: 384
Study: 23234420

Group type: EXPERIMENTAL
Intervention: Oral random generation (secondary task loading executive functions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory spatial localization task (secondary task loading spatial working memory)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Articulatory suppression (secondary task loading phonological loop)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poor planning group
Number of subjects: 0
Study: 21641186

Group type: EXPERIMENTAL
Intervention: Syringe-fed CLP babies
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cup-and-spoon-fed CLP babies
Number of subjects: 57

Group type: COMPARATOR
Intervention: Normal breast-fed babies
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cup-and-spoon-fed CLP babies (artificial and breast milk)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Normal babies
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Cup-and-spoon-fed babies
Number of subjects: 57
Study: 19602903

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease patients (CKD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 155
Study: 16525576

Group type: EXPERIMENTAL
Intervention: 100 mg oral aspirin for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 325 mg oral aspirin for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro aspirin (150 micromol/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NS398 (COX-2 inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SB203580 (p38-MAPK inhibitor)
Number of subjects: 0
Study: 12612386

Group type: EXPERIMENTAL
Intervention: LP stent
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Guidant stent
Number of subjects: 1003
Study: 11115036

Group type: COMPARATOR
Intervention: 150 mL/kg per day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 200 mL/kg per day
Number of subjects: 54
Study: 9118717

Group type: EXPERIMENTAL
Intervention: Annual chest radiographs (CXRs) with sputum cytologic findings in the experimental group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular and frequent rescreening CXRs in the experimental group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sporadic and/or infrequent rescreening in the control group
Number of subjects: 0
Study: 1332974

Group type: EXPERIMENTAL
Intervention: Biodegradable polyglycolic acid rods
Number of subjects: 30

Group type: COMPARATOR
Intervention: Kirschner wires
Number of subjects: 30
Study: 3490803

Group type: EXPERIMENTAL
Intervention: Propofol (2.2 mg kg‐1 body weight, reduced to 1.8 mg kg‐1 with opioids and benzodiazepins)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 100
Study: 29248753

Group type: EXPERIMENTAL
Intervention: Vitamin D (300000 Unit, single intramuscular injection)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 26689781

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 300 µg and intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA) alone
Number of subjects: 45
Study: 24936901

Group type: EXPERIMENTAL
Intervention: Braking force of 11% of body mass (BM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Braking force of 8.7% of body mass (BM)
Number of subjects: 16
Study: 22680789

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 258

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Overall opioids
Number of subjects: 258
Study: 19889470

Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Domperidone (30 mg/day)
Number of subjects: 32
Study: 18794551

Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg orally once daily
Number of subjects: 371

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg orally once daily
Number of subjects: 371
Study: 15983794

Group type: EXPERIMENTAL
Intervention: Tyrosine depletion (TPD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: D1/D2 receptor stimulation under TPD conditions (using pergolide)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12017399

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10406826

Group type: EXPERIMENTAL
Intervention: BNP (3.0 pmol. kg(‐1). min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ADM (2.7 pmol. kg(‐1). min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ADM (5.4 pmol. kg(‐1). min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ADM and BNP combined
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7726426

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 8 micrograms/kg (Group C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 4 micrograms/kg + morphine 2 mg (Group CM)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Epidural morphine 50 micrograms/kg (Group M)
Number of subjects: 45
Study: 2285385

Group type: EXPERIMENTAL
Intervention: Himega (2 g/day or 4 g/day of n‐3 fatty acid)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Triglyceride-based fish oil (2 g/day or 4 g/day of n‐3 fatty acid)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Himega (2 g/day of n‐3 fatty acid)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 22
Study: 7231917

Group type: EXPERIMENTAL
Intervention: Epinephrine hydrochloride (1% base)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 29265941

Group type: EXPERIMENTAL
Intervention: Job club program
Number of subjects: 87

Group type: COMPARATOR
Intervention: Supported employment
Number of subjects: 87
Study: 31188145

Group type: EXPERIMENTAL
Intervention: Ozone injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 30
Study: 27864015

Group type: EXPERIMENTAL
Intervention: ePCR model (ensemble of penalised Cox regression models)
Number of subjects: 2346

Group type: EXPERIMENTAL
Intervention: Reference model (based on eight clinical variables and a penalised Cox proportional-hazards model)
Number of subjects: 2346

Group type: EXPERIMENTAL
Intervention: ENTHUSE M1 cohort validation
Number of subjects: 2346

Group type: COMPARATOR
Intervention: Meta-analysis across all methods
Number of subjects: 2346
Study: 25849358

Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal, 1.5 mA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham tDCS (control)
Number of subjects: 100
Study: 22494086

Group type: EXPERIMENTAL
Intervention: Expressive writing about breast cancer
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Expressive writing about breast cancer trauma
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Expressive writing about facts related to breast cancer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no writing)
Number of subjects: 120
Study: 22352083

Group type: EXPERIMENTAL
Intervention: Early intervention (10-session standardized school trauma intervention - Cognitive Behavioral Intervention for Trauma in Schools)
Number of subjects: 123
Study: 18070731

Group type: EXPERIMENTAL
Intervention: Anterior hiatal repair
Number of subjects: 102

Group type: COMPARATOR
Intervention: Posterior hiatal repair
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 16854848

Group type: EXPERIMENTAL
Intervention: AVF blood-flow surveillance by ultrasound dilution (Qa surveillance group)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Usual treatment (control group)
Number of subjects: 137
Study: 15251034

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (75 mg BID)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11878519

Group type: EXPERIMENTAL
Intervention: Controlled hypotension (CH) induced by sodium nitroprusside (mean arterial pressure (MAP) 50 mm Hg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of controlled hypotension (CH) and acute normovolaemic haemodilution (ANH) (post‐ANH haematocrit 29%; intraoperative MAP 50 mm Hg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard anaesthesia (control)
Number of subjects: 42
Study: 9061079

Group type: EXPERIMENTAL
Intervention: Low-compression ultrasound (9:1)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: High-compression ultrasound (15:1)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Uncompressed ultrasound
Number of subjects: 67
Study: 8227787

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 61
Study: 2868824

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29438121

Group type: EXPERIMENTAL
Intervention: Lotrafilcon B (Air Optix; Ciba Vision)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comfilcon A (Biofinity; Coopervision)
Number of subjects: 60
Study: 27867438

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal Sleep (NS)
Number of subjects: 27
Study: 24061546

Group type: EXPERIMENTAL
Intervention: Combined orthostatic hypotension criteria
Number of subjects: 8788

Group type: EXPERIMENTAL
Intervention: Systolic orthostatic hypotension
Number of subjects: 8788

Group type: EXPERIMENTAL
Intervention: Diastolic orthostatic hypotension
Number of subjects: 8788
Study: 22991208

Group type: EXPERIMENTAL
Intervention: Controlled reoxygenation CPB
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hyperoxic/standard CPB
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Comparison of hyperoxic/standard vs. controlled reoxygenation CPB
Number of subjects: 49
Study: 20089558

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg b.i.d.
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg b.i.d. in sarcopenic patients with BMI < 25 kg/m²
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sorafenib 400 mg b.i.d. in non-sarcopenic patients and/or overweight or obese
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sorafenib 800 mg/day in sarcopenic male patients with BMI < 25 kg/m²
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sorafenib 800 mg/day in male patients above the cut-off for sarcopenia
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sorafenib 800 mg/day in male patients with BMI > 25
Number of subjects: 55